Urteste SA
Research Urteste SA (URT) on Bullrun: market cap PLN 65.62M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerURT
- ExchangeWAR
- CountryPoland
- SectorHealthcare
- IndustryBiotechnology
- CurrencyPLN
- Market capPLN 65.62M
- Financial periodQ1 2026
- RevenuePLN 2.00K
- Net income-PLN 1.86M
- Free cash flow-PLN 7.08M
- Gross margin-4100.0%
Valuation Snapshot
latest market cap is PLN 65.62M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | PLN 21.00K | n/a | n/a | -1123.8% | n/a | PLN 1.86M | PLN 2.98M | PLN 24.93M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-28 | PLN 65.62M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 PLN.
About Urteste SA
Urteste S.A. engages in the research and development of diagnostic tests for cancers in Poland. It offers diagnostic tests for pancreas, prostate, kidney, colon, liver, biliary tract, bile ducts, stomach, lung, esophagus, ovary, endometrium, blood, breast, and brain. The company was incorporated in 2021 and is based in Gdansk, Poland.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Urteste SA's market cap?
Urteste SA's market capitalization is PLN 65.62M.
What does Urteste SA do?
Urteste S.A. engages in the research and development of diagnostic tests for cancers in Poland. It offers diagnostic tests for pancreas, prostate, kidney, colon, liver, biliary tract, bile ducts, stomach, lung, esophagus, ovary, endometrium, blood, breast, and brain. The company was incorporated in 2021 and is based in Gdansk, Poland.